APDN

 

APDN 2.07 -0.08 -3.72%
Investor Relations | SEC Filings | Key Metrics | @YMB | @SA | @Benzinga | @iHub
Original Content from StoryTrading:
  • APDN update from Annual Shareholder’s Meeting (6/8/2016) -  I attended the annual shareholder’s meeting today and wanted to provide an update. I’ll first give an overview, and then dig down into each vertical. Overview The meeting was comprehensive and well put together. All directors attended except for one and every member of the executive team was there along with some lower level employees. There were stations setup with More »
  • APDN Revenue up 7% YoY (2/10/2016) -  My quick thoughts on today’s results and conference call. I managed to ask two questions on the call… — SUMMARY and My Conclusions… 1. Revenue was in-line with my Q1 estimate 2. Company re-affirmed > $3.6M cotton revenue and > $9.0M company revenue for the year 3. Growth focus beyond cotton this year will be DNANet, Polyester, and Polyolefins. It’s More »
  • APDN up 27% as it Reports Record Q4 Revenue of $4M, a 517% increase over Q4 2014, and 75% Sequential Increase over Q3 (12/14/2015) -  APDN filed their 10-K tonight for fiscal year 2015 ending September 30th and they reported $4M in revenue for Q4 and $9M in revenue for the year. For the quarter, APDN beat analyst estimates by 100%. Q4 revenue was a 517% increase over Q4 2014. FY revenue of $9M was a 230% increase over 2014. Additionally, APDN reported an adjusted More »
  • APDN Poised to Report 200% – 440% Revenue Increase Tonight. $5 – $7 Near-term Upside and $15 12-month Target. (12/14/2015) -  This is a quick earnings preview on APDN. For full coverage see the other APDN articles on the site. APDN is set to report earnings for it’s Fiscal Q4 and FY 2015 after the close today. APDN will file a 10-K after the close. They typically file around 5pm EST. This will be followed by a PR between 5am and More »
  • CORRECTION: CEO Suggests APDN will be Profitable in Quarter Ending September, NOT December! (11/21/2015) -  This is an important correction to a story published on StoryTrading on November 19th, titled “APDN up 10% as Short Perpetrator Reported to Authorities & CEO Suggests Company will be Profitable in Quarter Ending December 31st.” Below you’ll see why this title should have read “September 30th” at the end. Upon carefully re-reviewing the webcast, it appears that Dr. Hayward, CEO More »
  • November 12th E-mail from Patrick Cox Explains how APDN was able to get “PumpStopper” to go on the Run (11/19/2015) -  Check out the below email from Patrick Cox written on November 12th. After you read this, you will understand how APDN was able to get the PumpStopper to go on the run by shutting down his website and his Twitter. Soon we may see the SA hit piece removed as well. * the source for the below email is a More »
  • APDN up 10% as Short Perpetrator Reported to Authorities & CEO Suggests Company will be Profitable in Quarter Ending December 31st (11/19/2015) -  This is a fast-breaking and developing update to our refutation of the APDN short piece written on SeekingAlphha. There are 3 catalysts TODAY causing the stock to pop: This morning, APDN issued a press release reporting that they have identified the short author of the SA article along with his co-conspirator. Both have been reported to the Fed and the More »
  • APDN Revenue Set to Surge 480% as Shorts Fabricate False Story Line Ahead Of Record Results. (11/3/2015) -  Disclosures: I am long APDN. I wrote this article myself and it represents my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Summary Short article by “The Pump Stopper” created false story line about the “hype” of Patronus deal and published false information about More »
  • Patrick Cox Responds to Short Attack on APDN (11/3/2015) -  Excerpt of Newsletter from Patrick Cox: ” November 2, 2015 Bear Attack on Applied DNA Sciences (and Patrick) Creates Long-Term Buying Opportunity Dear TransTech Reader, Last Thursday was a rough one for shares of Applied DNA Sciences. No, the company did not release any negative news related to any of its products, nor did it issue a share dilution, or More »
  • APDN Eyes $10-$13 after Cotton Sales EXPLODE to 100 Million Pounds. (10/9/2015) -  Applied DNA Sciences, APDN, was first covered by Eli Carmean of StoryTrading when it was trading at just $2.55 on August 12th. Since then, the stock quickly met it’s initial target of $5 and Eli provided an update on September 21st when it was trading at $6.06 and published a $7 target. Subsequent to this, APDN topped out at $6.60 More »
  • Here’s an Update on our top Story Trades Ideas (10/7/2015) -  Good morning all! Been out of the office for some time and now back at my desk. A few quick updates on some Story Trades: APDN: Eli Carmean nailed this and our traders have been riding this from $2.55. The stock is at $6.06 now but it still has a long way to go. CBLI: An article was never published More »
  • APDN update after initial 100% target reached… (9/21/2015) -  The below article is an update to the original APDN article published on StoryTrading when APDN was trading at $2.55. At that time, a $5 target on the stock. That was before several additional catalysts came about. The stock closed on Friday at $6.06. The original article can be found here. ——————————- APDN Update First off – full disclosure – My personal price points More »
  • Updated Positions: CBLI, CAPN, APDN, ADAT, MEIP, ATNM, AIMT, WPCS and more… (9/16/2015) -  This is a quick update after the holiday this week. I’m back at my desk and in the chat room today. After two high-profile failed trades in RGSE and HOTR – I’ve regained footing in the past 2 weeks and now have a very promising story trade portfolio which is performing very well. My current long positions are CBLI, CAPN, More »
  • Applied DNA Sciences (APDN) – $5 Target (8/12/2015) -  New initiation: APDN (also APDNW) Industry: DNA science Last Trade: $2.55 Target: $5.00 Timeframe: EoY Market Cap: $55.2M Late June initiated position – Average $2.5-2.7 The Story Applied DNA sciences is principally devoted to developing DNA embedded biotechnology security solutions. The technology can be utilized in a variety of industries such as textiles/clothing, electronics, pharmacies, ink, etc. I feel as though APDN More »

Events:
#APDN
#APDN Excerpt of Newsletter from Patrick Cox:
(this was posted in a comment on SeekingAlpha and subsequently deleted by SA)

-----
Noah Katz
I subscribe (See more) to Patrick Cox biotech investment newsletter; here's an excerpt of an email I received today:

" November 2, 2015
Bear Attack on Applied DNA Sciences (and Patrick) Creates Long-Term Buying Opportunity

Dear TransTech Reader,

Last Thursday was a rough one for shares of Applied DNA Sciences.

No, the company did not release any negative news related to any of its products, nor did it issue a share dilution, or anything else that would have a material effect on APDN’s value.

Instead, an anonymous article was published on the website Seeking Alpha that attempted to smear the reputation of APDN, its management, and our editor, Patrick Cox. If you’d like to read it for yourself, it can be found here.

As a team, we hate having to respond to these types of baseless reports, published via a questionable financial website by an anonymous user hiding behind his computer with little to no repercussions. However, this user has caused severe short-term damage to the company’s share price, and thus needs to be responded to.

First, neither Patrick nor anyone on the analyst team has ever had any direct or indirect financial arrangement with Applied DNA Sciences, or any company in our portfolio. John Mauldin does sit on the board of three companies we’ve recommended; however, we include a disclosure any time those companies are so much as mentioned in our weekly and monthly pieces.

Other than the baseless smear campaign lodged against Patrick, the article covered perceived issues with the company’s technology, management, and fundamentals, among other things.

Applied DNA's technology is an integral part of the US military's growing response to the very real threat of cyberwarfare. Before mandating and subsidizing the use of this technology in critical military supply lines, the Pentagon thoroughly tested and validated the company's DNA biotechnology and the operations by which it is deployed. As such, Applied DNA is a de facto part of America's military/intelligence network.

Like other defense contractors, we assume that the company is closely monitored by the military to avoid compromising the technology and its use. The lack of openness about the company's military contracts can be frustrating to some, but it is a necessary part of doing business as a defense industry supplier. More important for investors, it is also a sign that APDN is operating within the military and intelligence industry's scrutiny and rules.

For anyone that still has doubts about APDN’s tight knit connection to the US military, here’s a document from the Defense Logistics Agency on how it uses APDN’s SigNature DNA marking technology in order to monitor and trace sensitive shipments.

The user went on to attack the company’s technology, calling it “1999 era Chinese technology.”

The Department of Defense requires the use of APDN’s technology in its supply lines in order to ensure that everything from cases of ammunition to PATRIOT missiles end up where they need to be.

The Department of Defense is and has been working directly with APDN to implement DNA authentication as part of its cybersecurity efforts and is routinely at the APDN facilities. If anything had been amiss at the company—let alone if it were a shell company as the Seeking Alpha user asserts—I think someone in the government would have noticed.

Although some of APDN’s investors have been involved with failed companies in the past, particularly Crede Capital Group, this isn’t uncommon in the biotech space. Most companies do not turn into multi-billion dollar firms; many fail and/or sell their intellectual property to other companies. This is the nature of the biotech business… and really, business in general. Many of the world’s richest men have made and lost fortunes dozens of times; it’s what entrepreneurs do!

And although APDN’s financing agreement may seem odd when looked at in the context of a large, established company, APDN is still very small and growing. For instance, the point made by the Seeking Alpha user that CEO James Hayward agreed to a dilutive financing arrangement with Arjent Limited that was somehow underhanded in nature is misleading. Dilutive financing agreements are an integral part of the capital raising process and are anything but unusual— especially for small, publicly traded biotechs like APDN.

As for the attacks on APDN’s fundamentals, all you have to do is look at the company’s audited financial statements to see for yourself. At one point, the user went so far as to claim APDN has “no assets.” That statement is false as APDN has over $14.1 million in assets, compared to $1.6 million in liabilities on its balance sheet. If you want to take a look for yourself, click here

The part that really makes us wonder how anyone took this fraud seriously is in the very first sentence, where the user makes no secret that he and his company are short APDN. Right off the bat, you should know he’s biased and trying to drive the price down for his own personal gain.

The article on Seeking Alpha is littered with half-truths and innuendos meant to scare investors into selling for the author’s personal gain—at the expense of a company doing great work. Many of our long-time subscribers have seen this before and understand that this is part of the business. For new ones who haven’t yet experienced a bear raid like this, I feel your pain.

However, one thing that these events do is make stock prices much cheaper than their intrinsic value. Remember: nothing related to the company’s operations changed last week; the fundamentals are still intact..."
Please sign up or sign in to like or comment on this post.
#APDN maxim group report
Please sign up or sign in to like or comment on this post.